Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ENDRA Life Sciences (NDRA) Research & Development (2016 - 2025)

ENDRA Life Sciences has reported Research & Development over the past 6 years, most recently at $1.4 million for Q4 2021.

  • Quarterly Research & Development rose 24.43% to $1.4 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2021, down 7.36% year-over-year, with the annual reading at $1.8 million for FY2025, 42.01% down from the prior year.
  • Research & Development was $1.4 million for Q4 2021 at ENDRA Life Sciences, up from $1.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $2.0 million in Q4 2019 and troughed at $95814.0 in Q1 2017.
  • The 5-year median for Research & Development is $1.3 million (2017), against an average of $1.2 million.
  • Year-over-year, Research & Development tumbled 51.82% in 2017 and then soared 1641.73% in 2018.
  • A 5-year view of Research & Development shows it stood at $1.4 million in 2017, then decreased by 22.72% to $1.1 million in 2018, then surged by 92.99% to $2.0 million in 2019, then crashed by 43.63% to $1.1 million in 2020, then increased by 24.43% to $1.4 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Research & Development are $1.4 million (Q4 2021), $1.2 million (Q3 2021), and $1.7 million (Q2 2021).